Merkel cell carcinoma in pelvic lymph nodes after surgical staging for endometrial cancer: A case report and review of the literature  by Thomakos, Nikolaos et al.
M
e
N
A
a
b
a
A
R
A
A
K
M
N
P
E
1
t
c
a
m
w
L
d
s
o
p
c
A
G
2
hCASE  REPORT  –  OPEN  ACCESS
International Journal of Surgery Case Reports 3 (2012) 340– 342
Contents lists available at SciVerse ScienceDirect
International  Journal  of  Surgery  Case  Reports
j ourna l ho me  pa ge: www.elsev ier .com/ locate / i j scr
erkel  cell  carcinoma  in  pelvic  lymph  nodes  after  surgical  staging  for
ndometrial  cancer:  A  case  report  and  review  of  the  literature
ikolaos  Thomakosa, Dimitrios  Zacharakisa,∗, Nikolaos  Akrivosa, Flora  Zagourib, Maria  Simoua,
ristotle Bamiasb,  Meletios-Athanassios  Dimopoulosb, Alexandros  Rodolakisa, Aris  Antsaklisa
First Department of Obstetrics and Gynecology, National and Kapodistrian University of Athens, “Alexandra” Hospital, Athens, Greece
Department of Clinical Therapeutics, National and Kapodistrian University of Athens, “Alexandra” Hospital, Athens, Greece
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 11 February 2012
ccepted  7 March 2012
vailable online 5 April 2012
eywords:
erkel cell carcinoma
euroendocrine tumor
elvic  lymph nodes
ndometrioid adenocarcinoma
a  b  s  t  r  a  c  t
INTRODUCTION:  Merkel  cell  carcinoma  (MCC)  is a rare malignant  neuroendocrine  tumor  of  the  skin.
PRESENTATION OF  CASE:  We  present  a case  of  MCC  in  pelvic  lymph  nodes,  revealed  after  surgical  staging
for  endometrial  cancer.  A  54-year-old  Caucasian  woman  presented  to our  department  with  a three-
month  history  of  postmenopausal  bleeding.  After  proper  preoperative  evaluation,  the  patient  underwent
total  abdominal  hysterectomy,  bilateral  salpingo-ophorectomy  and  pelvic  lymph  node  dissection.  The
pathology  report  conﬁrmed  the  presence  of  a small,  grade  I, endometrioid  adenocarcinoma  and  MCC  in
the  pelvic  lymph  nodes.  Primary  site  of the disease  could  not  been  retrieved.  The  tumor  board  decided
adjuvant  chemotherapy  (carboplatin  and  etoposide)  and  close  follow-up  every  2 months.  Our  patient  is
alive  with  no  evidence  of  disease  12 months  after  surgery.
DISCUSSION:  It  is  noteworthy  that  19%  of  the  patients  with  MCC  had  lymph  node  metastasis  with  no
apparent  primary  lesion.  The  mechanism  of  this  regression  remains  unclear,  although  a  higher  apoptotic
activity  has  been  observed  in  MCC  than  other  skin  tumors.  In  addition,  other  co-malignancies  have  also
been  linked  to MCC  patients.  The  explanation  for the  frequent  occurrence  of  other  primary  neoplasms  in
patients  with  MCC  is  still unclear.  However,  a reasonable  cause  could  be an  altered  genetic  proﬁle  or  an
immuno-compromised  situation  in  these  patients.
CONCLUSION: Further  analytic  investigations  are  needed  to  clarify  the  role  of  various  factors  in the  spon-
taneous  regression  or not  of this  neuroendocrine  tumor  as  well  as  in  the  simultaneous  genesis  of  other
primary  carcinomas.
gical © 2012 Sur
. Introduction
Merkel cell carcinoma (MCC) is a rare malignant neuroendocrine
umor of the skin, ﬁrst described by Toker in 1972 as “trabecular
arcinoma”.1 It mainly affects elderly Caucasians, presenting at an
verage age of 69 years with immunosuppressed patients being the
ost susceptible to the disease.2 Sun-exposed areas of the skin as
ell as lower extremities appear to be most frequently involved.
ocal recurrences and dissemination to regional lymph nodes and
istant organs (liver, lung, bones) are characteristics of this aggres-
ive tumor.2
However, rare cases of MCC  conﬁned to a lymph node with-
ut an apparent primary site have been reported.3–7 It has been
roposed that MCC  originates from immature totipotent stem
ells that acquire neuroendocrine characteristics upon malignant
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transformation.6 The occasional presence of squamous or eccrine
differentiation in these tumors also suggests stem cell origin.8
Herein, we present a case of MCC  in pelvic lymph nodes, revealed
after surgical staging for endometrial cancer. To our knowledge,
pelvic nodal involvement has never been reported in literature as
a clinical presentation of the disease.
2. Case presentation
A  54-year-old Caucasian woman  presented to our department
with a three-month history of postmenopausal bleeding. Her med-
ical history was  unremarkable while her obstetrical included 2
uncomplicated full-term vaginal deliveries and one ﬁrst trimester
miscarriage.
Pelvic examination revealed normal size uterus and adnexae,
without signiﬁcant bleeding through the external cervical os.
Transvaginal ultrasound showed an endometrial thickness of
12 mm.  Dilatation and curettage followed and histology disclosed
Open access under CC BY-NC-ND license.a well-differentiated endometrioid adenocarcinoma of the uterus.
After proper preoperative evaluation, our patient underwent thor-
ough surgical staging including total abdominal hysterectomy,
bilateral salpingo-ophorectomy and pelvic lymph node dissection.
 BY-NC-ND license.
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Fig. 1. Positive immunohistochemical staining for cytokeratin 20.
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oig. 2. Scant eosinophilic cytoplasm, round nuclei and multiple nucleoli on HE.
The pathology report conﬁrmed the presence of a small, grade
, endometrioid adenocarcinoma with superﬁcial invasion of the
yometrium and no extension to the cervix. A block of lymph
odes from the right parametrium were ﬁlled with multiple solid,
mall monomorphic tumor cells with large, oval, pale nuclei. Dis-
ersed chromatin, scanty cytoplasm and multiple nucleoli were
resent. Lymph nodes from the left parametrium were negative for
athological ﬁndings. Immunohistochemical stains were positive
or CK20 (Figs. 1 and 2) in a dot-like perinuclear pattern, synap-
ophysin (Fig. 3) and pankeratin and negative for LCA, Bcl-2, CD3,
D20, CK7, Vimentin, CD99 and CK5/6. In addition, S-100, HMB-
5 and TTF-1 were also not expressed, excluding the possibility
f certain metastasis (melanoma, thyroid, lung, brain). With such
Fig. 3. Tumor cells are positive for synaptophysin.PEN  ACCESS
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a staining proﬁle, a diagnosis of MCC  in pelvic lymph nodes was
assumed.
Abdominal computed tomography of the chest and abdomen
performed in our patient after surgery, as well as evaluation by
a consultant dermatologist could not reveal primary site of the
disease. The tumor board decided that adjuvant chemotherapy
(carboplatin and etoposide) and close follow-up every 2 months
was the correct course of action. Our patient is alive with no evi-
dence of disease 12 months after surgery.
3.  Discussion
MCC  is an uncommon tumor with an annual incidence of
approximately 0.2–0.45 cases per 100,000 inhabitants.9 In a review
of 661 cases conducted in 2000, 2% presented with an unknown
primary site.10 However, in a later series from Australia, 19% of the
patients with MCC  had lymph node metastasis with no apparent
primary lesion.11
Hypotheses that have been proposed to explain the existence
of an epithelial tumor conﬁned to a lymph node are: (a) malig-
nant transformation of a pre-existing intranodal epithelial nest,
(b) spread from a primary tumor that regressed after metasta-
sis to the node and (c) origin from a subset of lymphoreticular
cells which share cytokeratin pattern and endocrine features
with epithelial cells.12 It is still unclear to us whether our case
represents a primary or metastatic MCC.Primary tumors, most
often of the skin (squamous and basal cell carcinoma) as well as
hematological malignancies (non-Hodgkin lymphoma) have been
associated with MCC  patients.13–15 Adenocarcinomas of the breast
and ovaries have also been linked to the disease. Endometrial
cancer has not been related to MCC  and pelvic nodal involve-
ment as part of this rare neoplasm has never been reported in
literature.It is noteworthy that all co-malignancies, whether they
appear before, after or simultaneously with MCC, behave more
aggressively.16,17 The explanation for the frequent occurrence of
other primary neoplasms in patients with MCC  is still unclear. How-
ever, a reasonable cause could be an altered genetic proﬁle or an
immuno-compromised situation in these patients.18 Our patient
has been free of disease for 12 months; close follow-up (evaluation
by a dermatologist every 2 months and CT scans every 6 months)
has not revealed primary site or recurrence.
Considering the reported incidence of MCC, the estimated rate
of spontaneous regression is higher than expected (1.7–3%).19
The mechanism of this regression remains unclear, although a
higher apoptotic activity has been observed in MCC  than other skin
tumors. It has been suggested that T-cell related cytokines such
as interferons have a leading role in the spontaneous regression
of neuroendocrine tumors.20 We  truly hope that this will be the
scenario for our patient.
4.  Conclusion
In conclusion it can be said that MCC  represents a diagnostic
dilemma with difﬁcult therapeutic criteria. Further analytic inves-
tigations are needed to clarify the role of various factors in the
spontaneous regression or not of this neuroendocrine tumor as
well as in the simultaneous genesis of other primary carcinomas.
Because of its rare incidence and variable clinical presentations,
a multidisciplinary approach is usually of crucial importance in
establishing management guidelines.Conﬂict of interest statement
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